The effect of CKD on HbA1c is a clinically important consideration for anyone managing diabetes alongside kidney disease. HbA1c is the standard marker of long-term glycaemic control, but chronic kidney disease introduces several physiological changes — including shortened red blood cell lifespan, anaemia, and uraemia-related biochemical interference — that can render this measurement unreliable. In moderate-to-advanced CKD, HbA1c values may significantly underestimate true glucose exposure, risking under-treatment of hyperglycaemia. Understanding these limitations is essential for safe, individualised diabetes management in line with NICE, UKKA, and ABCD guidance.
Summary: CKD causes HbA1c to underestimate true blood glucose levels primarily by shortening red blood cell lifespan and through uraemia-related biochemical interference, making the test unreliable in moderate-to-advanced kidney disease.
- Shortened red blood cell lifespan in CKD reduces glycation time, producing an artificially low HbA1c even when blood glucose is elevated.
- Uraemia causes carbamylation of haemoglobin, which can interfere with certain HbA1c assay methods; the degree of interference is method-dependent.
- Anaemia, erythropoiesis-stimulating agents (ESAs), iron therapy, and blood transfusions all further distort HbA1c readings in CKD patients.
- Continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) are preferred alternatives in CKD stages 4–5, as they are independent of haematological variables.
- Metformin must be dose-reduced when eGFR falls below 45 mL/min/1.73 m² and discontinued below 30 mL/min/1.73 m² due to lactic acidosis risk (NICE NG28, MHRA guidance).
- Referral to nephrology or a renal diabetes service is indicated when eGFR falls below 30 mL/min/1.73 m², there is rapid CKD progression, or glycaemic management becomes complex.
Table of Contents
- How Chronic Kidney Disease Affects HbA1c Readings
- Why HbA1c May Be Unreliable in CKD
- Alternative Glycaemic Monitoring in Kidney Disease
- NICE and NHS Guidance on Diabetes Management in CKD
- Clinical Implications for Interpreting HbA1c Results
- When to Seek Specialist Review for Diabetes and CKD
- Frequently Asked Questions
How Chronic Kidney Disease Affects HbA1c Readings
CKD shortens red blood cell lifespan due to uraemia and haemolysis, reducing glycation time and producing an artificially low HbA1c that may mask poor glycaemic control, particularly in CKD stages 3b–5.
Haemoglobin A1c (HbA1c) is a widely used marker of long-term glycaemic control, reflecting average blood glucose levels over the preceding two to three months. It is reported in IFCC units (mmol/mol); where percentage values are also quoted, these are provided in parentheses for reference. HbA1c works by measuring the proportion of haemoglobin that has become glycated — a process that occurs naturally when glucose binds irreversibly to haemoglobin within red blood cells. In healthy individuals, this provides a reliable snapshot of glucose management. However, in patients with chronic kidney disease (CKD), several physiological changes significantly distort this measurement.
One of the most important mechanisms involves red blood cell lifespan. In CKD, uraemia and associated haemolytic processes shorten the survival of red blood cells. Because HbA1c accumulates over the lifespan of a red cell, a shorter lifespan means less time for glycation to occur — even if blood glucose levels are elevated. The result is an artificially low HbA1c, which may give a falsely reassuring picture of glycaemic control.
Additionally, many patients with CKD develop anaemia, often managed with erythropoiesis-stimulating agents (ESAs) or iron supplementation. Both conditions and their treatments alter red blood cell turnover, further complicating HbA1c interpretation. Blood transfusions, which introduce donor red cells of varying ages, can also unpredictably skew results. These combined effects mean that in moderate-to-advanced CKD (stages 3b–5), HbA1c values may not accurately represent a patient's true glycaemic burden — though the degree of distortion varies by assay method and the extent of anaemia or ESA use — potentially leading to under-treatment of hyperglycaemia. Clinicians should review any interpretative comments provided by the local laboratory alongside the HbA1c result, particularly where anaemia, ESA use, or recent transfusion is documented. This is consistent with guidance from the UK Kidney Association (UKKA) and the Association of British Clinical Diabetologists (ABCD) on diabetes management in CKD.
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Why HbA1c May Be Unreliable in CKD
HbA1c becomes increasingly unreliable as CKD advances due to carbamylation interference, altered red cell turnover from anaemia, and bidirectional effects of iron deficiency or haemolytic anaemia on red cell lifespan.
Beyond red blood cell lifespan, there are additional biochemical reasons why HbA1c becomes an unreliable marker as kidney function declines. Carbamylation is one such process — in uraemia, elevated urea levels lead to the formation of carbamylated haemoglobin, which can interfere with certain laboratory assays used to measure HbA1c. The extent of this interference is method-dependent: modern HPLC, enzymatic, and boronate affinity methods aligned with IFCC standards are generally less susceptible, but interference cannot be excluded in all cases. Clinicians should check with their local laboratory regarding the assay method in use and any known interferences relevant to CKD or uraemia, in line with guidance from the Association for Clinical Biochemistry and Laboratory Medicine (ACB).
The degree of unreliability tends to correlate with the severity of CKD. In earlier stages (CKD 1–3a), HbA1c generally remains a useful tool, though clinicians should remain alert to confounding factors. As kidney function deteriorates — particularly in CKD stages 4 and 5, including those on dialysis — the discordance between HbA1c and actual glycaemic control becomes clinically significant. Studies have demonstrated that in dialysis patients, HbA1c can underestimate true glucose exposure by a meaningful margin.
It is also worth noting that iron deficiency anaemia, common in CKD, can paradoxically raise HbA1c by prolonging red cell lifespan, while haemolytic anaemia lowers it. This bidirectional effect makes interpretation particularly challenging without knowledge of the patient's full haematological picture. Clinicians should therefore:
-
Review the patient's renal function (eGFR and CKD stage)
-
Assess haemoglobin levels and red cell indices
-
Consider whether the patient is receiving ESAs, iron therapy, or has had recent transfusions
-
Check local laboratory notes on HbA1c assay methodology and any flagged interferences
These contextual factors are essential before drawing conclusions from an HbA1c result in any patient with known or suspected CKD.
Alternative Glycaemic Monitoring in Kidney Disease
CGM-derived metrics such as time in range (TIR) are the most reliable alternatives in advanced CKD, as they are independent of haematological variables; fructosamine and glycated albumin are limited by hypoalbuminaemia.
Given the limitations of HbA1c in CKD, clinicians and patients may need to rely on complementary or alternative markers of glycaemic control. Fructosamine is one such option, measuring glycated serum proteins — primarily albumin — and reflecting average glucose levels over the preceding two to three weeks. Because it is independent of red blood cell lifespan, it avoids many of the confounders affecting HbA1c. However, fructosamine is influenced by serum albumin levels, which are frequently low in CKD due to protein loss or malnutrition, limiting its reliability in this population. Its use should be discussed with the local laboratory and interpreted with caution in the context of hypoalbuminaemia.
Glycated albumin offers a similar short-term window and has been studied in dialysis patients, with some evidence suggesting it may reflect glycaemic exposure more accurately than HbA1c in this group. However, this evidence remains preliminary, standardisation is limited, and glycated albumin is not yet widely available in routine NHS practice. Like fructosamine, it is unreliable in significant hypoalbuminaemia or malnutrition. 1,5-anhydroglucitol (1,5-AG) is another marker that reflects postprandial glucose excursions, but it is importantly confounded by renal dysfunction and glycosuria — both common in CKD — and is not currently recommended for routine clinical use in this population.
In practice, self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) are increasingly important tools for patients with diabetes and CKD. Real-time CGM (rt-CGM) and intermittently scanned CGM (isCGM/flash) devices provide glucose data and trend information that is entirely independent of haematological variables. NICE recommends CGM for adults with type 1 diabetes (NG17), children and young people with diabetes (NG18), and adults with type 2 diabetes on insulin (NG28). For patients with CKD in whom HbA1c is unreliable, CGM-derived metrics — including time in range (TIR), time below range, and glucose variability — offer a more accurate and actionable picture of day-to-day glycaemic control. Eligibility criteria for NHS-funded CGM continue to evolve; clinicians should refer to current NICE guidance and local NHS commissioning arrangements.
NICE and NHS Guidance on Diabetes Management in CKD
NICE NG203 and NG28 recommend individualised HbA1c targets in CKD, support SGLT2 inhibitor use where eGFR thresholds are met, and advise metformin dose reduction below eGFR 45 and discontinuation below eGFR 30.
NICE provides specific guidance on the management of both type 1 and type 2 diabetes, as well as dedicated guidance on CKD (NICE guideline NG203). Together, these documents acknowledge the complexity of managing glycaemia in the context of declining renal function. NICE recommends that HbA1c targets should be individualised, taking into account the risk of hypoglycaemia, patient preferences, comorbidities, and the reliability of the measurement itself — all of which are particularly pertinent in CKD (NICE NG17, NG28, NG203).
For patients with type 2 diabetes and CKD, NICE guidelines NG28 and NG203 highlight the importance of SGLT2 inhibitors such as dapagliflozin and empagliflozin, which have demonstrated significant renoprotective and cardiovascular benefits in clinical trials (DAPA-CKD, EMPA-KIDNEY). These agents are recommended for patients meeting specific eGFR and urinary albumin-to-creatinine ratio (uACR) thresholds as set out in NG203 and NG28; clinicians should refer to current NICE guidance and the relevant Summary of Product Characteristics (SmPC, available via the electronic Medicines Compendium) for up-to-date licensed indications and renal thresholds. Importantly, their glucose-lowering efficacy diminishes as eGFR falls, so they should not be relied upon solely for glycaemic management in advanced CKD.
NICE and the MHRA advise caution with metformin in CKD. In line with NICE NG28, the BNF, and the MHRA Drug Safety Update on metformin and renal impairment, metformin should be reviewed and the dose reduced when eGFR falls below 45 mL/min/1.73 m², and it should be discontinued when eGFR falls below 30 mL/min/1.73 m², due to the risk of lactic acidosis. Patients and carers should be advised to report any suspected adverse effects — including symptoms that may suggest lactic acidosis — via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).
Insulin regimens may require careful adjustment in CKD. Renal insulin clearance decreases as kidney function declines, which often reduces insulin dose requirements and increases the risk of hypoglycaemia. Insulin doses should be reviewed regularly as eGFR changes, and patients should be counselled accordingly. The NHS Long Term Plan and NHS Diabetes Programme both emphasise integrated care between primary care, nephrology, and diabetes teams to optimise outcomes in this high-risk group.
Clinical Implications for Interpreting HbA1c Results
HbA1c results in CKD must always be interpreted alongside eGFR, haemoglobin, haematinics, and assay method; triangulation with CGM or SMBG data is essential in CKD stages 4–5 to avoid under- or over-treatment.
Understanding the effect of CKD on HbA1c has direct implications for clinical decision-making. A clinician who takes an HbA1c result at face value in a patient with stage 4 CKD and anaemia may significantly underestimate the degree of hyperglycaemia, potentially delaying intensification of treatment. Conversely, an artificially elevated HbA1c in a patient with iron deficiency could prompt unnecessary escalation of therapy, increasing hypoglycaemia risk.
When interpreting HbA1c in the context of CKD, it is helpful to consider the following practical points:
-
Always review eGFR and CKD stage alongside the HbA1c result
-
Check haemoglobin and haematinics — anaemia, iron deficiency, and recent transfusions all affect interpretation
-
Consider the assay method used by the local laboratory; check for any interpretative comments on HbA1c reliability in the context of CKD, uraemia, or anaemia, as some methods are more susceptible to carbamylation interference than others
-
Triangulate with SMBG or CGM data where available, particularly in CKD stages 4–5 or in patients on dialysis (NICE NG17, NG28; UKKA/ABCD guidance)
-
Avoid rigid HbA1c targets in patients with advanced CKD; individualised goals that prioritise avoiding hypoglycaemia are more appropriate, in line with NICE NG17, NG28, and NG203
-
Document the limitations of HbA1c in the clinical record to ensure future clinicians interpret results in the correct context
From a patient safety perspective, hypoglycaemia is a particular concern in CKD. Reduced renal gluconeogenesis, decreased renal insulin clearance, altered drug clearance, and dietary restrictions all increase vulnerability. Patients and carers should be educated about hypoglycaemia recognition and management, and medication regimens should be reviewed regularly as kidney function changes. Any suspected adverse drug reactions should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).
When to Seek Specialist Review for Diabetes and CKD
Specialist nephrology or renal diabetes review is indicated when eGFR falls below 30 mL/min/1.73 m², there is rapid eGFR decline, recurrent hypoglycaemia, or persistent discordance between HbA1c and self-monitored glucose readings.
The coexistence of diabetes and CKD represents a high-risk clinical scenario that often warrants input from specialist teams. Patients should be referred to or reviewed by a nephrology or renal diabetes service when eGFR falls below 30 mL/min/1.73 m² (CKD stage 4), when there is rapid progression of kidney disease, or when glycaemic management becomes increasingly complex due to the unreliability of monitoring tools and changing drug pharmacokinetics.
Referral triggers consistent with NICE NG203 that should prompt timely specialist review include:
-
Persistent or unexplained discordance between HbA1c and self-monitored glucose readings
-
Recurrent hypoglycaemia, particularly in patients on insulin or sulphonylureas
-
Significant deterioration in eGFR — a sustained decline of ≥5 mL/min/1.73 m² per year, or a drop of ≥25% and a change in CKD category within 12 months
-
A Kidney Failure Risk Equation (KFRE) score of greater than 5% over five years
-
New or worsening proteinuria (uACR ≥70 mg/mmol, or uACR ≥30 mg/mmol in the presence of haematuria)
-
Difficulty achieving individualised glycaemic targets despite optimised therapy
-
Consideration of renal replacement therapy, including dialysis or transplantation
Patients themselves should be encouraged to contact their GP or diabetes nurse if they notice increased or severe hypoglycaemic episodes — severe or recurrent hypoglycaemia warrants urgent clinical review via NHS 111, urgent care, or the diabetes team as appropriate — symptoms of uraemia (nausea, fatigue, reduced urine output), or if their glucose readings appear inconsistent with how they feel. Shared care between primary care, diabetes teams, and nephrology — supported by structured care plans — is essential to navigate the complexities of this dual diagnosis safely.
Not sure if this is normal? Chat with one of our pharmacists →
In summary, the effect of CKD on HbA1c is clinically significant and multifactorial. Awareness of these limitations, combined with the use of complementary monitoring strategies and adherence to NICE-aligned guidance (NG203, NG28, NG17), enables safer and more effective management of diabetes in patients with kidney disease.
Frequently Asked Questions
Why does CKD cause HbA1c to be falsely low?
In CKD, uraemia and haemolytic processes shorten red blood cell lifespan, leaving less time for glucose to bind to haemoglobin. This means HbA1c accumulates less than expected, producing a falsely low result even when blood glucose levels are actually elevated.
What monitoring should be used instead of HbA1c in advanced CKD?
Continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) are recommended alternatives in CKD stages 4–5, as they provide glucose data independent of red blood cell lifespan or haematological variables. NICE supports CGM use in eligible patients with diabetes on insulin.
At what eGFR level should metformin be stopped in CKD?
According to NICE NG28, the BNF, and MHRA guidance, metformin should be dose-reduced when eGFR falls below 45 mL/min/1.73 m² and discontinued when eGFR falls below 30 mL/min/1.73 m² due to the risk of lactic acidosis.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
